Xilio TherapeuticsXLO
13F holders, Q1 2024 (March 31)31holders
2famous investors
$1.08avg. 13F price*
At the end of Q1 2024, 31 institutions reported holding Xilio Therapeutics Inc. (XLO) in their 13F filings. The largest holders were Bain Capital Life Sciences Investors, LLC ($3.0M), FMR LLC ($2.1M) and Takeda Pharmaceutical Co. Ltd. ($1.6M). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Xilio Therapeutics Inc.
- CUSIP
- 98422T100
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $513K |
| Exits | 8 | $1.4M |
Ownership 31 holders
| Bain Capital Life Sciences Investors, LLC | 0.24% | No change | 2,805,413 | $3.0M |
| FMR LLC | 0.00% | No change | 1,907,671 | $2.1M |
| Takeda Pharmaceutical Co. Ltd. | 0.55% | No change | 1,475,121 | $1.6M |
| RiverVest Venture Management LLC | 19.12% | No change | 1,441,444 | $1.6M |
| Rock Springs Capital Management LP | 0.04% | No change | 1,440,759 | $1.6M |
| Atlas Venture Life Science Advisors, LLC | 0.10% | Reduce -64.0% | 992,912 | $1.1M |
| Vanguard Group Inc. | 0.00% | No change | 902,531 | $975K |
| Balyasny Asset Management L.P. | 0.00% | New | 338,542 | $366K |
| Renaissance Technologies | 0.00% | Add +18.9% | 249,446 | $269K |
| Morgan Stanley | 0.00% | Add +74.4% | 221,905 | $240K |
| FIL Ltd | 0.00% | No change | 218,705 | $236K |
| Geode Capital Management, LLC | 0.00% | No change | 84,826 | $92K |
| Bridgeway Capital Management, LLC | 0.00% | Reduce -54.3% | 71,081 | $77K |
| Millennium Management | 0.00% | Add +131.3% | 70,198 | $76K |
| BlackRock Inc. | 0.00% | Reduce -3.2% | 45,355 | $49K |
| SevenBridge Financial Group, LLC | 0.01% | New | 31,000 | $37K |
| PFG Investments, LLC | 0.00% | New | 30,000 | $32K |
| Prelude Capital Management, LLC | 0.00% | New | 29,500 | $32K |
| FNY Investment Advisers, LLC | 0.02% | New | 27,500 | $29K |
| Northern Trust Corp. | 0.00% | No change | 17,798 | $19K |
| Summit Trail Advisors, LLC | 0.00% | New | 16,000 | $17K |
| State Street Corp. | 0.00% | No change | 15,690 | $17K |
| Dunhill Financial, LLC | 0.01% | No change | 10,274 | $16K |
| Charles Schwab Investment Management Inc. | 0.00% | No change | 11,925 | $13K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -20.2% | 11,153 | $12K |
| JPMorgan Chase & Co. | 0.00% | Reduce -4.0% | 2,744 | $3K |
| Royal Bank of Canada | 0.00% | Add +13.9% | 533 | $1K |
| Key Financial Inc | 0.00% | No change | 830 | $896 |
| UBS Group AG | 0.00% | No change | 201 | $217 |
| Wells Fargo & Company | 0.00% | Add +1.9% | 108 | $117 |
| Qube Research & Technologies Ltd | 0.00% | No change | 4 | $4 |
"% of holder's portfolio" is XLO's weight in each manager's 13F, not the share of Xilio Therapeutics Inc. the manager owns.